Extended Data Fig. 2: SerBut did not exhibit significant therapeutic efficacy in relapsing-remitting EAE. | Nature Biomedical Engineering

Extended Data Fig. 2: SerBut did not exhibit significant therapeutic efficacy in relapsing-remitting EAE.

From: A serine-conjugated butyrate prodrug with high oral bioavailability suppresses autoimmune arthritis and neuroinflammation in mice

Extended Data Fig. 2

a. Experimental schema. EAE was induced in SJL/J mice using PLP139-151/CFA with 100 ng pertussis toxin. Starting on day 19, mice were regrouped into two treatment groups with equivalent average clinical score, and received twice daily oral gavage of either PBS (n = 6) or SerBut (n = 8) at 24 mg/dose. b. Disease progression as indicated by the clinical score. c. The percentage of CD11b+CD45low microglia cells of live cells in the spinal cord. d-h. The percentage of CD11b+CD11c+(d), RORγ+CD4+Foxp3−(e), CD4+Foxp3+(f), CD4+PD-1+(g), PD-1+CD4+Foxp3+(h) of CD45+ cells in the spinal cord. Data represent mean ± s.e.m. Statistical analyses were performed using Student’s t-test.

Source data

Back to article page